NEW YORK, May 2, 2018 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQ: ESPR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-…
